...Shuxin Xiao; Chuanbo Fan; Jinlong Ma; Hongwei Xue; Liqin Xu Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma...

...Ho-Jin Shin; Do-Young Kim; JooSeop Chung; Kyung-Hwa Shin; Hyungi Lee Introduction: The effects of lymphocyte subtypes, including helper (Th), natural killer (NK), and regulatory (Treg) cells, and other T-cell subtypes on treatment outcomes in diffuse large B-cell lymphoma (DLBCL) patients...

...Pier Luigi Zinzani; Marco Bregni; Mario Spione; Manfred Mitterer; Gerardo Musuraca; Annamaria Bugli; Francesco Piazza; Antonello Pinto Introduction: Treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) represents a challenge for clinicians due to the lack of therapeutic...

...Marianna Gentilini; Beatrice Casadei; Alessandro Broccoli; Lisa Argnani; Michele Cavo; Pier Luigi Zinzani There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory...

...Yang Xia; Xinlian Zhang MYC, as a powerful transcription factor, plays a vital role in various cancers. The clinical significance of MYC alterations in diffuse large B-cell lymphoma (DLBCL) has been investigated for a long time. In this study, we comprehensively summarize the different alterations...

... with diffuse large B-cell lymphoma (DLBCL). Methods: A total of 46 DLBCL patients treated with pre-ASCT were enrolled in the present study, and two methods, Deauville score and maximal standardized uptake value reduction (ΔSUV max ), were used to evaluate the PET/CT scans before transplantation. Results...

...TingBo Liu; LiHong Chen; Jie Pan; LiLi Pan; JianDa Hu; ZhongYou Ji Background: The International Prognostic Index (IPI) scoring system is the most widely used prognostic tool for diffuse large B-cell lymphoma (DLBCL); however, it fails to consistently identify patients with poor outcomes...

... liver nodularity, which led to the diagnosis of a primary liver diffuse large B-cell lymphoma. Discussion: We review the evidence supporting possible mechanisms of lymphomagenesis after successful hepatitis C therapy, particularly involving late “second-hit” mutations after viral-induced DNA damage...

...Reyad Dada Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved...

...Francesco Malaspina; Cinzia Pellegrini; Beatrice Casadei; Lisa Argnani; Pier Luigi Zinzani Diffuse large B-cell lymphoma is the most frequent histology at diagnosis among non-Hodgkin B lymphomas and can be cured in 50-70% of cases after the first-line chemotherapy regimen. Patients who do...

... in diffuse large B-cell lymphoma (DLBCL) patients. Currently, the standard regimen is R-CHOP every 21 days. Methods: This is a phase II clinical trial of treatment with 6 cycles of R-CHOP-14 with pegfilgrastim support in 2 populations of previously untreated DLBCL patients aged ≥65 years (n = 73) or <65...

...Antica Duletić-Načinović; Vedrana Gačić; Toni Valković; Ksenija Lučin; Elizabeta Fišić; Marta Žuvić-Butorac; Irena Seili-Bekafigo; Nives Jonjić Background: Diffuse large B-cell lymphomas (DLBCL) are heterogeneous diseases, and the identification of additional DLBCL risk factors is especially...

...Chunhong Hu; Chao Deng; Wen Zou; Guangsen Zhang; Jingjing Wang Background: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP). The role of radiotherapy (RT) after complete response...

...Sung-Hoon Jung; Deok-Hwan Yang; Jae-Sook Ahn; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee We evaluated the relationship between serum lactate dehydrogenase (LDH) level with systemic inflammation score and survival in 213 patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP...

... patients with testicular lymphoma. One patient with diffuse large B-cell lymphoma (DLBCL) was lost to follow-up after diagnosis. Two patients with Burkitt's lymphoma had poor outcomes regardless of treatment. Thus, we analyzed the clinical features, treatments, and outcomes of 19 patients with DLBCL...

...S. Al-Humood; A. AlQallaf; S. Al-Shemmari; L. Al-Faris; B. Al-Ayadhy Epstein-Barr virus (EBV) has a pathogenic role in several lymphomas, including diffuse large B-cell lymphoma (DLBCL). EBV-associated genetic aberrations in DLBCL have not been fully characterized. The aim of this study...

...Kazunari Aoki; Sumie Tabata; Noboru Yonetani; Akiko Matsushita; Takayuki Ishikawa Background: A recent report showed that the combination of the absolute lymphocyte count (ALC) and the absolute monocyte count (AMC) at diagnosis gave a prognostic score in diffuse large B-cell lymphoma (DLBCL...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Behavioral alterations Diffuse large B-cell lymphoma MicroRNA miR-21 PDCD4 PTEN MicroRNAs (miRNAs) are endogenously expressed single...

... to in the content or advertisements. Aplastic anemia Diffuse large B-cell lymphoma Epstein-Barr virus Antithymocyte globulin Lymphoproliferative disorder Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) are becoming a serious problem with a recent increase in the number...

... transplantation or receiving chemotherapy. However, there have been few reports on the incidence and risk factors of HVIs in diffuse large B-cell lymphoma (DLBL) patients treated with rituximab combined chemotherapy. Methods: We analyzed 270 patients who were newly diagnosed with DLBL. All of the patients had...